Anvisa Prohibits Advertising of Semaglutida Pen
Anvisa, Brazil's health surveillance agency, has prohibited the advertising of Semavy, a semaglutida pen used to treat type 2 diabetes, due to irregular promotions on billboards at Congonhas Airport, the product's website, and social media. The medication, which requires a prescription, cannot be advertised to the general public according to Brazilian law. Hypera Pharma, the manufacturer, has been cooperative with Anvisa's directives.3 sourcesSee all sources
